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It is well established that the suppres-
sive effect of leptin on pancreatic b cell
function observed in vivo is relayed via
the hypothalamus, whereas the peripheral
leptin receptors on the b cell are not
involved in this action (Kalra, 2009).
Therefore, elevated serum leptin may
have affected in vivo insulin release by
a central effect—as acknowledged in our
paper—but for the suppression of insulin
secretion in vitro, it is of no consequence.
Concerning the different effects of high-
K+ stimulation between the two studies, it
is difficult to compare static incubations
with islets that have not been exposed to
any other modulator, with responses ob-
tained acutely in a perifusion experiment
after exposure to other secretagogues.
The concerns on ClC-3 localization
deserve to be thoroughly discussed: we
do not challenge our colleagues’ view
that ClC-3 preferentially localizes to
vesicles containing SLMV/endosomal
markers. However, these data do not
exclude that ClC-3 is also contained in
the LDCVs, albeit at a low density that
could still have physiological conse-
quences. Indeed, the present work on
insulin secretion/b cell exocytosis re-
ported by us and the Nelson group agrees
with the data of Maritzen et al. It is
intriguing that exocytosis in chromaffin
cells and pancreatic b cells was reduced
to the same extent by ablating ClC-3.
Thus, whatever the mechanism, it seems
clear that ClC-3 somehow affects exocy-
tosis in two different endocrine cells.
As to the preparation of our granule
preparation and the observed ClC3
enrichment, we point out that our immu-
noblots were performed using FACS-
sorted LDCVs labeled by EGFP-phogrin
without an IP step (Varadi et al., 2005).
ClC-3 was easily detected in the obtained
fraction, but for several reasons (the main
being possible insulin leakage from theLDCV fraction during spinning—differ-
ences in LDCV versus overall cellular pro-
teome that may be further affected by
EGFP-phogrin overexpression) we advise
against using this data as proof of strong
enrichment of ClC-3 in the LDCVs—
merely its presence.
Concerning the immunostaining of iso-
lated granules, the example shown was
not a singular event. However, the granule
preparation is fragile and the majority of
granules aggregate in clusters. Evaluation
of possible coexpression of granule
proteins only makes sense in selected
single granules or small clusters. The
incomplete overlap of the ClC-3 and
phogrin fluorescence signals is a purely
technical issue (a consequence of the
red confocal channel being slightly mis-
aligned) and was not observed in a simul-
taneous experiment in which another
secondary antibody/channel was used.
The red signal was in fact systematically
shifted by 200 nm (Figure S1) and the
possibility that the ClC-3 signal should
emanate from another organelle that
attaches the insulin granule in such a
systematic fashion seems quite unlikely.
Focusing on the coexpression of EGFP-
phogrin and ClC-3, the data set was
reanalyzed (and expanded) by another
investigator, with essentially identical
results. In total, 60 single particles of
granule size were found. Twelve of these
stained positive only for ClC-3, two only
for EGFP-phogrin, whereas the absolute
majority (46) were positive for both ClC-3
and phogrin. In summary, 77% of all
detected granular particles were positive
to both phogrin and ClC-3, whereas
when concentrating on the phogrin-posi-
tive granules 96% also stained for ClC-3.
The latter value corresponds to the
percentage given in the text; we apologize
for any lack of clarity. Furthermore, these
results suggest that this preparation
(another batch than the one used forCell Metabolism 1immunoblotting in the original paper)
may have had some contamination that
probably is of endosomal origin, but it is
equally clear that the absolute majority
comes from the phogrin-positive parti-
cles, i.e., LDCVs.
As for the concerns about the gold
particle staining, the image shown does
in fact contain several gold particles of
both sizes attached to the very same indi-
vidual granule as in any section investi-
gated (data not shown). We acknowledge
the concerns about suitability of the anti-
body. These experiments were added
during revision, when we unfortunately
no longer had access to KO tissue, but
such investigations would be welcomed.
Finally, several aspects of ClC-3 remain
to be elucidated. For example, it is clearly
not the onlymechanism involved as islets/
b cells fromClC-3-deficient animals retain
glucose-induced insulin secretion and
capacity to prime secretory granules,
albeit at a reduced rate. Thus, there is
a redundancy of mechanisms, and other
transport processes may substitute for
ClC-3 under some conditions. This may
perhaps explain the discrepancy between
our and Dr Jentsch’s unpublished data
using the mentioned b cell-specific
ClC-3 KO mouse that in our experiments
exhibited a 50% reduction in insulin
secretion and exocytosis.SUPPLEMENTAL INFORMATION
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